MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

MacroGenics Company Profile (NASDAQ:MGNX)

Consensus Ratings for MacroGenics (NASDAQ:MGNX) (?)
Ratings Breakdown: 1 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $40.25 (66.80% upside)

Analysts' Ratings History for MacroGenics (NASDAQ:MGNX)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016BTIG ResearchReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Leerink SwannReiterated RatingOutperform$47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016WedbushReiterated RatingOutperform$52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$37.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2016Janney Montgomery ScottInitiated CoverageBuy$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/5/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Stifel NicolausReiterated RatingBuy$51.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for MacroGenics (NASDAQ:MGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q1($0.67)($0.88)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($0.60)($0.88)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q2($0.44)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015$0.87($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015($0.36)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014($0.42)($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014($0.29)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014($0.09)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013$0.15$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for MacroGenics (NASDAQ:MGNX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.92)($0.46)($0.70)
Q2 20164($0.91)($0.48)($0.69)
Q3 20164($0.99)($0.51)($0.79)
Q4 20164($1.02)($0.54)($0.83)
Q2 20171($0.83)($0.83)($0.83)
(Data provided by Zacks Investment Research)
Dividend History for MacroGenics (NASDAQ:MGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for MacroGenics (NASDAQ:MGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.93View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for MacroGenics (NASDAQ:MGNX)
DateHeadline
06/25/16 04:47 PMMacroGenics Inc. (MGNX) Jumps 8.2% on June 23 - Equities.com
06/22/16 09:52 AMRecently Issued Stock Ratings For MacroGenics, Inc. (NASDAQ:MGNX) - Fiscal Standard
06/20/16 05:31 AMMacroGenics, Inc. (NASDAQ:MGNX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/14/16 04:55 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: MacroGenics Inc (NASDAQ: MGNX), Seattle ... - Analyst Ratings
06/10/16 05:09 AMMacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016) - [at noodls] - Bispecific molecule based on DART® platform simultaneously targets B-cell antigens, CD32B and CD79B MGD010 was well tolerated at all dose levels with no serious adverse effects ROCKVILLE, Maryland, June ...
06/07/16 05:21 PMMacroGenics Inc. (MGNX) Jumps 6.9% on June 06 - Equities.com
06/06/16 08:51 AMPerformance Review for MacroGenics, Inc. (NASDAQ:MGNX) - HNN
06/04/16 05:10 PMWeekly Review: Eleven Biotherapeutics Inc (NASDAQ:EBIO), MacroGenics Inc (NASDAQ:MGNX) - Market News Call
06/03/16 05:37 PMMacrogenics Incorporated (NASDAQ:MGNX) Shorted Shares Increased By 3.36% - HNN
06/02/16 05:30 PMMacroGenics Inc. (MGNX) Jumps 5.78% on June 02 - Equities.com - MacroGenics Inc. (MGNX) Jumps 5.78% on June 02Equities.comMacroGenics Inc. (MGNX) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 5.78% to $27.44, representing a gain of $1.5 per share. Some 261,482 shares traded hands on 2,713 trades, compared with an average ...and more »
06/02/16 08:02 AMBuy, Sell Or Hold Rating For MacroGenics, Inc. (NASDAQ:MGNX)? - Share Trading News - Buy, Sell Or Hold Rating For MacroGenics, Inc. (NASDAQ:MGNX)?Share Trading News05/18/2016 – MacroGenics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 47 price target on the stock. 04/07/2016 – BTIG Research began new coverage on MacroGenics, Inc. giving the company a “buy” rating.and more »
06/01/16 08:00 AMStock Review and Earnings Check on MacroGenics, Inc. (NASDAQ:MGNX) - HNN - Stock Review and Earnings Check on MacroGenics, Inc. (NASDAQ:MGNX)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting MacroGenics, Inc. (NASDAQ:MGNX) to report quarterly EPS of $-0.71. The company's next earnings report is expected to be published on or ...and more »
05/29/16 06:57 PMMacrogenics Incorporated (NASDAQ:MGNX) Shorted Shares Increased 3.36% After Market Selling - HNN - Macrogenics Incorporated (NASDAQ:MGNX) Shorted Shares Increased 3.36% After Market SellingHNNThe short interest to Macrogenics Incorporated's float is 8%. The stock increased 2.30% or $0.55 on May 27, hitting $24.5. About 233,197 shares traded hands. MacroGenics Inc (NASDAQ:MGNX) has declined 13.12% since October 22, 2015 and is ...and more »
05/25/16 12:45 AMEarnings Review and Stock Rundown for MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Hints and News - Earnings Review and Stock Rundown for MacroGenics, Inc. (NASDAQ:MGNX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting MacroGenics, Inc. (NASDAQ:MGNX) to post ...and more »
05/23/16 12:20 PMStock Rating Review for MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Hints and News - Stock Rating Review for MacroGenics, Inc. (NASDAQ:MGNX)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.33 on shares of MacroGenics, Inc. (NASDAQ:MGNX). Covering analysts ...and more »
05/22/16 06:29 PMMacroGenics, Inc. (NASDAQ:MGNX) Reports Basic Consolidated EPS At $-0.6333 - Investor Newswire - MacroGenics, Inc. (NASDAQ:MGNX) Reports Basic Consolidated EPS At $-0.6333Investor NewswireFrom the parent firm, MacroGenics, Inc. (NASDAQ:MGNX) diluted EPS came at $-0.6333 for the year ended 2015-12-31. For the quarter ended 2015-12-31 it came at $-0.6333. MacroGenics, Inc. (NASDAQ:MGNX) posted net basic EPS of $-0.63 for the year ...
05/22/16 06:29 PMMacroGenics Inc (MGNX) is Trading Higher on Unusual Volume for May 19 - Equities.com - MacroGenics Inc (MGNX) is Trading Higher on Unusual Volume for May 19Equities.comMacroGenics Inc (MGNX) experienced unusually high volume on May. 19, as the stock gained 1.23% to a closing price of $21.32. The stock saw 483,289 shares trade hands over the course of the day on 3,488 trades. Given that the stock's average daily ...and more »
05/20/16 07:01 PMMacroGenics Inc (MGNX) Jumps 6.05% on May 20 - Equities.com - MacroGenics Inc (MGNX) Jumps 6.05% on May 20Equities.comMacroGenics Inc (MGNX) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 6.05% to $22.61, representing a gain of $1.29 per share. Some 288,323 shares traded hands on 2,984 trades, compared with an average ...and more »
05/20/16 01:20 PMMACROGENICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/19/16 07:02 PMMorning Buzz: Ignyta, Inc. (NASDAQ:RXDX), MacroGenics, Inc. (NASDAQ:MGNX), Atlanticus Holdings Corporation ... - KC Register - Morning Buzz: Ignyta, Inc. (NASDAQ:RXDX), MacroGenics, Inc. (NASDAQ:MGNX), Atlanticus Holdings Corporation ...KC RegisterMacroGenics, Inc. (NASDAQ:MGNX) announced a global collaboration and license agreement for MGD015, a preclinical bispecific molecule, with Janssen Biotech, Inc. This product candidate incorporates MacroGenics' proprietary Dual-Affinity Re-Targeting, ...
05/19/16 07:02 PMJohnson & Johnson (NYSE:JNJ) To Invest Up To $740 Mn In Partnership With MacroGenics Inc (NASDAQ:MGNX) - Johnson & Johnson (NYSE:JNJ) subsidary Janssen has agreed on a second partnership with MacroGenics Inc (NASDAQ:MGNX) for continued cancer R&D. In the new collaboration, Janssen will pay MacroGenics a $75 million license fee upfront and oversee future ...
05/19/16 01:12 PMMacroGenics scores drug licensing deal worth up to $740 million -
05/19/16 07:18 AMMacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : May 19, 2016 -
05/19/16 12:14 AMFDA Greenlights Bladder Cancer Drug, RPRX Up 30% After-hours, Mega Leap For MGNX - IMGN closed Wednesday's trading at $5.50, down 0.54%. In after hours, the stock was up 2.73% to $5.65. Shares of MacroGenics Inc. (MGNX) rose more than 16% on Wednesday after the company licensed its preclinical product candidate MGD015 to Janssen Biotech ...
05/18/16 07:04 PMShare Recap and Earnings Focus on MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Hints and News - Share Recap and Earnings Focus on MacroGenics, Inc. (NASDAQ:MGNX)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating MacroGenics, Inc.and more »
05/18/16 07:04 PMBio-pharma shines says Wedbush as MacroGenics, Relypsa, and Aimmune to Outperform - Aimmune shares closed up 0.86% at $14.15 on Wednesday. Another bio-pharma reiterated at Outperform by Wedbush was MacroGenics Inc (NASDAQ:MGNX) - whose shares raced 16.7% higher to $21.06 on Wednesday. Wedbush said its 12-month share price target on ...
05/18/16 04:32 PMWhy Charter Communications, MacroGenics, and TD Ameritrade Jumped Today -
05/18/16 11:29 AMMacrogenics (MGNX) Is Today's Strong On High Volume Stock - TheStreet.com - Macrogenics (MGNX) Is Today's Strong On High Volume StockTheStreet.comCompared to other companies in the Biotechnology industry and the overall market, MACROGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500. Net operating cash flow has significantly decreased to -$31.91 ...and more »
05/18/16 11:29 AMMacroGenics Inc. (MGNX) Is Climbing On Janssen Agreement - RTT News - FierceBiotechMacroGenics Inc. (MGNX) Is Climbing On Janssen AgreementRTT NewsMacroGenics Inc. (MGNX) announced a global collaboration and license agreement for MGD015 with Janssen Biotech Inc. Wednesday morning. MacroGenics gapped open higher this morning and has continued to rise in early trade. The stock is now up 4.14 ...MacroGenics Strikes Collaboration Deal with Janssen Biotech for MGD015 (NASDAQ:MGNX)Sonoran Weekly ReviewLeerink Partners Reiterates Outperform on Macrogenics (MGNX)StreetInsider.comMacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for ...GlobeNewswire (press release)FierceBiotechall 6 news articles »
05/18/16 11:29 AMMacroGenics Inc. (MGNX) Is Climbing On Janssen Agreement - (RTTNews.com) - MacroGenics Inc. ( MGNX) announced a global collaboration and license agreement for MGD015 with Janssen Biotech Inc. Wednesday morning. MacroGenics gapped open higher this morning and has continued to rise in early trade. The stock is now ...
05/18/16 06:42 AMMacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for Treatment of Cancer - [at noodls] - MacroGenics licenses MGD015 to Janssen $75 Million upfront license fee paid to MacroGenics MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S. and Canada profit ...
05/17/16 11:56 PMRevenue Update on MacroGenics Inc(NASDAQ:MGNX) - Trade Calls - Revenue Update on MacroGenics Inc(NASDAQ:MGNX)Trade CallsMacroGenics Inc(NASDAQ:MGNX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 4, 2016. Company reported revenue of $2.85M. Analysts estimated a revenue of $10.64M. Earnings per share ...
05/16/16 06:46 PMConsensus Rating Review for MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Hints and News - Consensus Rating Review for MacroGenics, Inc. (NASDAQ:MGNX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.33 on shares of MacroGenics, Inc. (NASDAQ:MGNX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/12/16 07:59 PMOppenheimerfunds, Inc. Adjusts Its Investment in MacroGenics, Inc. (MGNX) - Finance Daily - Oppenheimerfunds, Inc. Adjusts Its Investment in MacroGenics, Inc. (MGNX)Finance DailyOppenheimerfunds, Inc. raised its stake in MacroGenics, Inc. by 640 shares in its quarterly SEC filing. Its investment was worth $54,179,000 a decrease of $35,292,000 as of quarter end. Oppenheimerfunds, Inc. isn't the only one who has changed their ...
05/12/16 07:59 PMMacroGenics Inc (MGNX) Drops 5.27% on May 11 - Equities.com - MacroGenics Inc (MGNX) Drops 5.27% on May 11Equities.comMacroGenics Inc (MGNX) was one of the Russell 2000's biggest losers for Wednesday May 11 as the stock slid 5.27% to $17.62, a loss of $-0.98 per share. Starting at an opening price of $18.58 a share, the stock traded between $17.52 and $18.83 over the ...and more »
05/12/16 02:38 PMETF’s with exposure to MacroGenics, Inc. : May 12, 2016 -
05/12/16 12:04 PMMACROGENICS INC Financials -
05/11/16 04:07 PMMacroGenics to Present MGD010 Clinical Data at EULAR 2016 - [at noodls] - ROCKVILLE, Maryland, May 11, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based ...
05/11/16 12:59 AMMacroGenics Inc (MGNX) is Trading Higher on Unusual Volume for May 09 - Equities.com - MacroGenics Inc (MGNX) is Trading Higher on Unusual Volume for May 09Equities.comMacroGenics Inc (MGNX) experienced unusually high volume on May. 09, as the stock gained 3.53% to a closing price of $18.79. The stock saw 466,294 shares trade hands over the course of the day on 4,476 trades. Given that the stock's average daily ...
05/10/16 07:42 PMPerformance Recap and Target Perspective on MacroGenics, Inc. (NASDAQ:MGNX) - B.O.D.Y Confidential - Performance Recap and Target Perspective on MacroGenics, Inc. (NASDAQ:MGNX)B.O.D.Y ConfidentialIn the latest trading session, shares of MacroGenics, Inc. (NASDAQ:MGNX) moved +3.53%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, company ...and more »
05/10/16 11:38 AMMacroGenics, Inc. :MGNX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 06:48 AMFirst Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics - [at noodls] - ROCKVILLE, Md., May 10, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that its collaboration partner, Pfizer Inc. (NYSE: PFE), has advanced a bispecific antibody therapeutic ...
05/09/16 07:13 PMCheck on Analyst Ratings MacroGenics, Inc. (NASDAQ:MGNX) - B.O.D.Y Confidential - Check on Analyst Ratings MacroGenics, Inc. (NASDAQ:MGNX)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1.33 on shares of MacroGenics, Inc. (NASDAQ:MGNX). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 scale.and more »
05/09/16 07:13 PMTraders Are Watching: Cytori Therapeutics, Inc. (NASDAQ:CYTX), MacroGenics, Inc. (NASDAQ:MGNX), Westbury ... - KC Register - Traders Are Watching: Cytori Therapeutics, Inc. (NASDAQ:CYTX), MacroGenics, Inc. (NASDAQ:MGNX), Westbury ...KC RegisterMacroGenics, Inc. (NASDAQ:MGNX) announced that Scott Koenig , M.D., Ph.D., President and CEO, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV. The presentation will take place on ...and more »
05/08/16 09:19 PMAfter Last Week What Do Analysts Think Of MacroGenics, Inc. (NASDAQ:MGNX) - Share Trading News - After Last Week What Do Analysts Think Of MacroGenics, Inc. (NASDAQ:MGNX)Share Trading News11/04/2013 – Lazard Capital Markets began new coverage on MacroGenics, Inc. giving the company a “buy” rating. The share price of MacroGenics, Inc. (NASDAQ:MGNX) was down -3.71% during the last trading session, with a day high of 19.06. 218163 ...MacroGenics Inc (MGNX) Forecasted to Earn Q2 2017 Earnings of ($0.83) Per ShareWeb Breaking Newsall 2 news articles »
05/06/16 08:00 PMHealthcare Volatile Stocks: MacroGenics, Inc. (NASDAQ:MGNX), Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX ... - KC Register - Healthcare Volatile Stocks: MacroGenics, Inc. (NASDAQ:MGNX), Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX ...KC RegisterMacroGenics, Inc. (NASDAQ:MGNX) reported financial results for the quarter ended March 31, 2016. Cash, cash equivalents and investments as of March 31, 2016 were $304.4 million, compared to $339.0 million as of December 31, 2015. Total revenue ...and more »
05/05/16 08:33 PMMacrogenics (MGNX): Today's Weak On High Volume Stock - TheStreet.com - Web Breaking NewsMacrogenics (MGNX): Today's Weak On High Volume StockTheStreet.comTheStreet Quant Ratings rates Macrogenics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and ...MacroGenics Inc (MGNX) Releases Earnings Results, Misses Estimates By $0.21 EPSWeb Breaking NewsMacroGenics' (MGNX) CEO Scott Koenig on Q1 2016 Results - Earnings Call TranscriptSeeking Alphaall 5 news articles »
05/05/16 08:33 PMMacrogenics (MGNX): Today's Weak On High Volume Stock - See the FREE profile for MGNX NOW at Trade-Ideas More details on MGNX: MacroGenics, Inc., a biopharmaceutical company, focuses on discovering and developing antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune ...
05/04/16 08:50 PMEdited Transcript of MGNX earnings conference call or presentation 4-May-16 8:30pm GMT -
05/04/16 06:07 AMQ1 2016 MacroGenics Inc Earnings Release - Time Not Supplied -
About MacroGenics

MacroGenics logoMacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. The Company has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MGNX
  • CUSIP:
Key Metrics:
  • Previous Close: $24.13
  • 50 Day Moving Average: $23.45
  • 200 Day Moving Average: $21.95
  • P/E Ratio: N/A
  • P/E Growth: 0.03
  • Market Cap: $833.57M
  • Current Quarter EPS Consensus Estimate: $-2.47 EPS
Additional Links:
MacroGenics (NASDAQ:MGNX) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha